Enliven Therapeutics (NASDAQ:ELVN) Releases Earnings Results, Beats Expectations By $0.06 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06, FiscalAI reports.

Enliven Therapeutics Price Performance

ELVN stock traded up $0.46 during trading on Friday, reaching $40.75. The company had a trading volume of 606,389 shares, compared to its average volume of 742,574. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $48.53. The company has a market cap of $2.48 billion, a P/E ratio of -24.40 and a beta of 0.32. The business has a 50 day moving average of $37.05 and a 200 day moving average of $27.33.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. HC Wainwright increased their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 3rd. Mizuho increased their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Finally, The Goldman Sachs Group increased their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $47.80.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the transaction, the director owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. This represents a 16.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $83,000. Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $191,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.